Delivery Order SPE2DB20D1109-SPE2DB22FQ03G
- Not listed
- This federal contract award is for the pharmaceutical product Dupixent 300 mg/2 ml pen 2 ml, awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $17,516.49 firm-fixed-price delivery order was issued by the Defense Logistics Agency (DLA), a defense agency, with a performance location in Conshohocken, PA. The award has an ultimate completion date of June 2, 2023. Amerisourcebergen is a major pharmaceutical distributor that holds significant Indefinite Delivery Contracts...
- This federal contract award is for the delivery of Dupixent 200 mg/1.14 ml pens to the U.S. government. The award was issued to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., by the Defense Logistics Agency (DLA) Troop Support Medical. The contract has a ceiling value of $8,236.04 and an ultimate completion date of October 19, 2023. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at $4,167.61, is a delivery order for Dupixent 300 mg/2 ml pens. The award has an ultimate completion date of February 15, 2024. Amerisourcebergen is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role in supplying medical products to federal government agencies, particularly the Department of...
- This federal contract award, valued at $11,668.82, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract covers the delivery of Dupixent 300 mg/2 ml pen, a pharmaceutical product, with a performance period through December 5, 2023. The contract is a Firm Fixed Price Delivery Order, and was not set aside for any specific business type. Amerisourcebergen Drug Corp is a major pharmaceutical distributor...
- This federal contract award is for the pharmaceutical product Dupixent 300 mg/2 ml pen, awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,805.87 firm fixed price delivery order contract has a completion date of May 2, 2024 and was awarded by the Defense Logistics Agency (DLA), a defense agency. The contract is not designated with a set-aside requirement, indicating open competition. Amerisourcebergen holds a $999,999,999...
- This federal contract award is for the delivery of the pharmaceutical product Dupixent 300 mg/2 ml pen, valued at $21,554.12, awarded by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp, Corporate Office Division. The contract is a firm-fixed price delivery order with an ultimate completion date of August 1, 2024. This award is not associated with a set-aside designation. Amerisourcebergen, a major pharmaceutical distributor,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Dupixent 300 mg/2 ml pens. The $21,622.78 firm-fixed-price delivery order falls under Amerisourcebergen's larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical. This IDC, which runs through November 2026, serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Dupixent 300 mg/2 ml pens. The $5,083.16 firm fixed-price delivery order is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., that supports the DLA Troop Support Medical in providing pharmaceutical products and medical supplies to military treatment...
- This federal contract award is for the delivery of Dupixent 300 mg/2 mL pens to the Defense Logistics Agency (DLA), a defense agency. The $12,694.28 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on November 29, 2021, with a completion date of November 30, 2021. The contract was not set aside for any specific business type. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a $999,999,999...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order (DO) valued at $5,597.01 from the Defense Logistics Agency (DLA) for the pharmaceutical product Dupixent 300 mg/2 ml pen. The award has an ultimate completion date of December 4, 2023 and is a Firm Fixed Price contract. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that supplies a wide range of medical products to federal...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB22FQ03GDelivery Order
This federal contract award is for the pharmaceutical product Dupixent 300 mg/2 ml pen, awarded by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $7,448.11 firm fixed-price delivery order has a completion date of September 8, 2022. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that plays a critical role in supplying medical products to federal government agencies, particularly the Department of Defense (DoD) and Department of Veterans Affairs (VA) healthcare systems. The company holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, as well as a $750,000 IDC with the Department of Justice Federal Bureau of Investigation, covering a wide range of pharmaceutical and medical supplies. This contract award did not have a set-aside designation, indicating open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.4k | 9/7/22 |